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Abstract
Cytotoxicity and cell growth inhibition studies were performed for three distinct polynuclear platinum(II) complexes of
spermidine, which showed to have significant cytotoxic and antiproliferative properties on the HeLa cancer cell line. The
chemical environment of the metal centres in the drugs, as well as the coordination pattern of the ligand, were found to be
strongly determinant of their cytotoxic ability. In the light of the results gathered, the most effective anticancer compound
among the ones tested (IC50 = 5 WM) was found to be the one displaying three difunctional (PtCl2N2) moieties
((PtCl2)3(spd)2). Both the cytotoxic activity and the antiproliferative properties of the complexes studied showed to be
irreversible for all the concentrations tested. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Biogenic polyamines are low molecular weight
polycations, present in all cells of higher organisms
as well as in those of many microorganisms, where
they perform vital biological functions, namely in cell
proliferation and di¡erentiation [1^5]. Due to their
positive charge at physiological pH, these polyamines
interact with both DNA and RNA [6], being respon-
sible for the regulation and stabilization of the struc-
ture and activity of these biomolecules (in the case of
DNA, this probably occurs through neutralization of
the phosphate groups of the nucleic acid). The most
common biogenic polyamines are putrescine, 1,4-di-
aminobutane (H2N(CH2)4NH2), which is the ¢rst
amine in the polyamine pathway (biosynthesized
from arginine), and a precursor of spermidine
(H2N(CH2)3NH(CH2)4NH2) and spermine (H2N-
(CH2)3NH(CH2)4NH(CH2)3NH2) (Fig. 1). Because
of the absolute polyamine requirement for cell
growth, interference with polyamine biosynthesis
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can be a rather promising therapeutic approach
against neoplastic diseases. In fact, an increased
rate of those biosynthetic reactions has been un-
equivocally demonstrated in malignant processes
[7^10]. The enzymes ornithine decarboxylase, argi-
nine decarboxylase and polyamine oxidase, involved
in the biosynthesis and metabolism of these poly-
amines, are also possible targets for chemotherapy.
Despite the large number of reported studies on
the di¡erent functions of polyamines in living cells,
the exact nature of the biochemical mechanisms
through which they act is still unknown, and has
lately been the target of numerous research works.
Over the last decade several studies of the cytotoxic
properties of platinum(II) and palladium(II) com-
plexes of distinct polyamines have been carried out,
aiming at obtaining new anticancer, third-generation
drugs, displaying enhanced e⁄cacy and tissue specif-
icity relative to the nowadays clinically used com-
pounds [11^16]. In fact, DNA attack by metal com-
plexes depends strongly on the chemical nature of the
compound. For instance, the widely used drug cis-
platin (cis-diamminedichloroplatinum(II), CDDP
[17]), despite its well established anticancer proper-
ties, is associated to both severe toxic side e¡ects and
the development of resistance in certain cancer cells
[18], its e¡ectiveness being thus limited to a some-
what narrow range of human tumours.
In the last few years, a new class of compounds
comprising two CDDP-like Pd(II) or Pt(II) contain-
ing moieties (e.g. [PtCl(NH3)2] or [Pt(NH3)Cl2])
linked by a variable length alkanediamine chain,
have proven to display novel antitumour and DNA
binding properties (inducing irreversible BCZ tran-
sitions) both in vitro and in vivo. In some cases they
were even found to be active in cisplatin-resistant cell
lines [19^21], and have since been the object of in-
tense research [22^35]. In fact, such agents yield dif-
ferent types of DNA adducts, such as long distance
intra- and interstrand cross-links not available to
conventional, mononuclear metal complexes. In par-
ticular, the antiproliferative properties of compounds
with spermidine and spermine as bridging units be-
tween the metal ions have been studied by several
research groups, including that of Navarro-Ran-
ninger et al. [32^35]. The group of Farrell et al., in
turn, has lately reported the antitumour e⁄cacy of
polynuclear Pt(II) complexes containing diamine
(H2N(CH2)nNH2), putrescine-like molecules acting
as linkers (e.g. triplatinum BBR3464, now under pre-
clinical development in cisplatin-resistant cell lines
[16,30,31]).
In the present work, the analysis of the cytotoxic
and antiproliferative properties of di¡erent polynu-
clear Pt(II) complexes of spermidine as a bridging
linker, in a human cancer cell line was carried out.
This was an interactive study, the structural charac-
teristics of those compounds being determined
through vibrational spectroscopy methods and their
synthesis being adapted ^ namely in the number of
Pt(II) ions, the length of the polyamine linker(s) be-
tween metal centres and the £exibility of these li-
gands ^ according to the results of their cytotoxicity
and antiproliferative evaluation. Hopefully, in com-
bination with further spectroscopic (Raman and
FTIR) and theoretical (ab initio) studies performed
Fig. 1. Schematic representation of the protonated (cationic)
forms of the biogenic polyamines putrescine (1,4-diaminobu-
tane), spermidine and spermine. (Data obtained from theoreti-
cal calculations ([37]; Marques et al., unpublished data)).
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simultaneously on the same systems [36,37], new light
may be shed on their structure^activity relationships
at the molecular level, so that a better understanding
of the biochemical mechanisms underlying their tox-
icity can be achieved.
2. Materials and methods
2.1. Synthesis of the Pt(II) complexes
The compounds tested were (H3spd)2(PtCl4)3 (I),
[PtCl2(Hspd)]2(PtCl4) (II) and (PtCl2)3(spd)2 (III)
(spd = spermidine) (Fig. 2), synthesized according to
reported methods [34]. (Anal. found for
Pt3C14Cl12H44N6 : C, 12.72; H, 3.49; N, 6.37; Cl,
32.95. Anal. found for Pt3C14Cl8H40N6 : C, 14.27;
H, 3.50; N, 7.10; Cl, 23.94. Anal. found for
Pt3C14Cl6H38N6 : C, 15.38; H, 3.57; N, 7.80; Cl,
17.63.) (The elemental analyses were carried out at
the Microanalysis Laboratory, Chemistry Depart-
ment, University of Manchester and at the Butter-
worth Laboratory, Middlesex, UK.) Raman experi-
ments were also carried out, aiming at obtaining
further structural information on the complexes.
All compounds studied are water soluble. Solu-
tions were prepared in concentrations ranging from
1.0U1035 M to 1.0U1034 M in phosphate bu¡ered
saline solution (PBS): 132.0U1033 M NaCl,
4.0U1033 M KCl; 1.2U1033 M NaH2PO4 ;
1.4U1033 M MgCl2 ; 6.0U1033 M glucose;
1.0U1032 M HEPES (N-[2-hydroxyethyl]piperazine-
NP-[4-butanesulphonic acid]). MTT (3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was
prepared in a concentration of 0.5 mg/ml in PBS
solution containing 1.0U1033 M CaCl2.
2.2. Chemicals
The HeLa cell line was obtained from the Ameri-
can Type Culture Collection (ATCC) (Rockville,
MD, USA). Culture media, antibiotics, Trypan
blue, phenol red, MTT, inorganic salts and acids
(of analytical grade) were purchased from Sigma-Al-
drich (Madrid, Spain). Fetal calf serum was obtained
from Biochrom (Berlin, Germany). Cisplatin was a
gift from Bristol-Myers Squibb (Portugal).
2.3. Cell culture
HeLa cells ^ an epithelial-like adherent cell line
from human cervix adenocarcinoma ^ were grown
in monolayers and maintained at 37‡C under 5%
CO2 in Dulbecco’s modi¢ed Eagle’s high glucose
(4500 mg/l) medium (DMEM-HG), supplemented
with 10% heat-inactivated fetal calf serum, glutamine
(1.168 g/l) and antibiotics (100 units of penicillin and
100 mg streptomycin). The cells were subcultured
twice a week, using a dissociation medium composed
of 136.9U1033 M NaCl, 2.7U1033 M KCl,
8.2U1033 M Na2HPO4, 1.5U1033 M KH2PO4,
4.0U1034 M EDTA (ethylenediaminetetraacetic
acid, disodium salt, dihydrate) (pH 7.4) and contain-
ing 400 Wl of a 1% (w/v) phenol red solution.
2.4. Toxicity and cell growth inhibition studies
Cytotoxicity and cell density evaluation after drug
exposure ^ for drug concentrations between 5 and
100 WM ^ were assessed by cell growth inhibition
assays. Cells were plated at 1^5U105 cells/ml on
12-well dishes. Twenty-four hours after seeding,
drug solutions were added to the medium and the
cultures were incubated at 37‡C. Cells were harvested
and analysed (both in controls and in drug-treated
cultures) every 24 h for a total period of 3^5 days
(depending on the compound used). Reversibility of
the drug e¡ect was tested by removing the drug and
adding fresh culture medium on the last day of in-
Fig. 2. Schematic representation of the Pt(II) complexes
studied.
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cubation with the drug, and assessing the cell viabil-
ity following 3 more days of incubation. Cell density
and viability were determined by Trypan blue exclu-
sion on single-cell suspensions obtained from the
monolayer cultures. Cell viability was further as-
sessed by mitochondrial dehydrogenase activity ^
MTT colorimetric assay. All experiments were per-
formed in triplicate.
The MTT assay for cell injury is based on the
ability of mitochondrial dehydrogenases of viable
cells to reduce MTT to a purple formazan product
(insoluble in water) [38] which can be quanti¢ed
spectrophotometrically [39,40] (after solubilization
in isopropyl alcohol containing 40 mM HCl). For
each time point, the culture medium was aspirated
and 1 ml of MTT solution (5 mg/ml in PBS) was
added to the cells (both control and drug-treated
cells) which were incubated for 4 h at 37‡C. After
this period, the formazan crystals formed were dis-
solved upon addition of 1 ml of 0.04 M HCl in iso-
propanol and the absorbance of these solutions was
measured at 570 nm (against a blank containing
MTT and HCl/isopropanol in a 1:1 ratio). The re-
sults were expressed as the percentage of MTT re-
duction, assuming the absorbance of control cells as
100%.
The 50% inhibitory concentration (concentration
of drug required to inhibit cell growth by 50%,
IC50) was calculated for each drug tested from
dose^response curves (for incubation periods of 48
and 72 h).
3. Results and discussion
The distinct complexes tested for both their cyto-
toxic and antitumour activity di¡er mainly in the
chemical environment of the Pt(II) centres, their £ex-
Fig. 3. Time- and dose-dependent antiproliferative e¡ects of complexes I, II and III on HeLa cells. 3.0U105 cells/ml were incubated
with the drugs for 24^72 h. Every 24 h, aliquots of the cell suspensions were removed and the cell density was evaluated by the Try-
pan blue exclusion method (as described in Section 2). In addition, the drug was removed 72 h after seeding and the cell density was
assessed following a further incubation of 72 h. The data represent the average þ mean standard deviation from experiments carried
out in triplicate. The following drug concentrations are represented: (A) 25 WM; (B) 50 WM; (C) 75 WM; (D) 100 WM. (Values for cis-
platin are included for comparison. Cell density for the control: 24 h, 6.3U105 cells/ml; 48 h, 9.5U105 cells/ml; 72 h, 14.0U105 cells/
ml; 144 h, 23.2U105 cells/ml.)
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ibility and their total electric charge. Thus, while
complex I is an ionic species (with a zero net charge),
II and III are cationic covalent compounds, closely
related except for the number of metal centres di-
rectly bound to the spermidine molecules (Fig. 2).
In fact, the triamine acts as a bidentate N,NP-donor
ligand ^ forming six-membered rings through coor-
dination to Pt(II) ^ its terminal protonated amino
groups being free in complex II, and bound through
a third metal centre in III (which reduces signi¢-
cantly the motional freedom of this compound).
Although both complexes II and III are difunctional
in each metal centre, the former has two CDDP-like
structures as opposed to III which has three, yielding
(upon hydrolysis) four and six coordination sites to
the DNA helix, respectively (Fig. 2). Moreover, com-
pound III displays a longer, stretched geometry with
six protonated, positively charged nitrogen atoms. It
should be noted that, apart from covalent binding,
both electrostatic interactions and formation of hy-
drogen bonds between the polyamine chain and the
nucleic acid backbone play a very important role in
the mechanism of complex^DNA interaction [41],
being thus determinant of the cytotoxic and antipro-
liferative action of these compounds. Factors such as
the di¡erential transport mechanisms of the drug
(e.g. across cellular membranes) are also closely as-
sociated to its cytotoxic activity and are strongly de-
pendent on the charge of the complex as well as on
the conformational characteristics of the ligand(s).
Fig. 3 represents the cell density variation as a
function of the incubation time of the cells with the
three distinct Pt(II) complexes tested, for di¡erent
drug concentrations. Fig. 4 displays the dose-depen-
dent cytotoxic e¡ects on HeLa cancer cells of those
compounds. By analysing these data, it is clear that
only for drug concentrations of approx. 50 WM or
higher may compounds I and II be considered to
Fig. 4. Time- and dose-dependent cytotoxic e¡ects of complexes I, II and III on HeLa cells. 1^5U105 cells/ml were incubated with
the drugs for 24^72 h. Every 24 h, aliquots of the cell suspensions were removed and cell viability was evaluated by the MTT colori-
metric assay (as described in Section 2). In addition, the drug was removed 72 h after seeding and the cell viability was assessed fol-
lowing a further incubation of 72 h. The data are expressed as a percentage of the control MTT reduction (100%) and represent the
average þ mean standard deviation from experiments carried out in triplicate. The following drug concentrations are represented:
(A) 25 WM; (B) 50 WM; (C) 75 WM; (D) 100 WM. (Values for cisplatin are included for comparison.)
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have signi¢cant cytotoxic and antiproliferative prop-
erties, while complex III displays by far the highest
cytotoxic and antitumour activity for concentrations
equal to or higher than 25 WM. Experiments to eval-
uate both cell viability and cell density were also
carried out for drug concentrations of 5^20 WM,
but no cytotoxic or antiproliferative activity was de-
tected.
These results are most probably due to the struc-
tural features of compounds I, II and III, described
above, namely the fact that complex III is the only
one to display three CDDP-like moieties, which
understandably seems to render it much more prone
to interact with the DNA helix. In the case of com-
plex II, instead, each Pt(II) ion binds to two hydro-
lysable chlorine atoms and to two nitrogens of the
polyamine ligand, the remaining of the (protonated)
spermidine backbone being free to interact ^ favour-
ably or unfavourably ^ with neighbouring groups in
the double helix. As to compound I, its ionic nature
provides it with particular features, re£ected as
shown in less signi¢cant antiproliferative and cyto-
toxic characteristics. However, despite the di¡erent
chemical features of complexes I and II they display
a very similar activity on HeLa cells, which seems to
highlight the fact that the number of metal centres is
a most important, if not determinant, factor govern-
ing the cytotoxic and antiproliferative properties of
this kind of metal complexes.
Table 1 illustrates the IC50 values for the com-
pounds tested. As expected from the previously dis-
cussed data, complex III displays the lowest IC50
value (5 WM), followed by compounds II (13 WM)
and I (20 WM). In the light of these results, com-
plexes II and III may be regarded as having potential
cytotoxic and antitumour activity [42].
Following drug treatment, a cell line may or may
not be able to restore its activity. In the case of
cancer cells, the degree of reversibility of the cyto-
toxic and antiproliferative e¡ects displayed by com-
pounds aimed for use as antitumour drugs is of the
utmost importance. All complexes studied showed an
irreversible e¡ect against HeLa cells for concentra-
tions equal to or higher than 50 WM (Fig. 4). In fact,
for high drug concentrations (100 WM) a drastic de-
crease of cell viability was observed ^ similar to the
one detected for cisplatin ^ even after incubation of
the cells with drug-free medium for an extra 72 h
period (Fig. 4D).
The results obtained in the present work for Pt(II)
complexes II and III are in good accordance with
previous cytotoxicity studies carried out for the
same compounds in human breast (MDA-MB468)
and leukaemia (HL-60) cell lines [34]. On the con-
trary, compound I was found to behave as a good
antiproliferative agent on MDA-MB468 and HL-60
cells [34] but not on HeLa cells ^ IC50 approx. 2.5
and 2.3 WM, respectively, vs. 20 WM obtained in the
present work. In the previously reported study, how-
ever, the antitumour activity of these complexes was
determined by cell density measurements only [34].
Also, no viability evaluation was performed, nor was
the reversibility of the drugs tested. Based on their
results, those authors proposed that the polyamine
complexes induce changes in the secondary as well
as in the tertiary structure of the DNA double helix
(even leading, in some cases, to a shortening e¡ect)
[34].
Farrell and coworkers have also recently reported
the synthesis and antitumour properties of several
di- and trinuclear Pt(II) complexes with bridging
diamine linkers (of varying chain lengths)
[16,26,29^31], that displayed high activity both in
vitro and in vivo, namely against cancer cell lines
resistant to cisplatin. These covalent compounds,
however, are distinct from the ones tested in the
present study, since they contain two PtCl(NH3)2
moieties linked by linear polyamine groups, as op-
posed to complexes II and III, in which the metal ion
is coordinated to two or more nitrogens from sper-
midine molecules. This chelate formation leads to a
signi¢cant £exibility decrease and consequently a dif-
ferent mechanism will be involved in the interaction
with DNA.
Table 1
Cytotoxic potency (IC50) of the Pt(II) complexes on HeLa cells
Complex IC50 (WM)
I 20.0
II 13.0
III 5.0
Cisplatin 2.0
IC50 values were calculated from dose^response curves for a 72
h drug exposure. Data were obtained through independent mea-
surements of cell viability by the MTT assay and the Trypan
blue exclusion method.
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The antitumour properties of Pt(II) complexes is
believed to be strongly dependent on the nature of
the bonding at the metal centre, namely on the elec-
tronic character of the Pt^X (X = halogen) and Pt^
ligand bonds, which underlies the relevance of the
structural knowledge that can be gathered through
the use of spectroscopic techniques, namely vibra-
tional spectroscopy. The Raman pattern now ob-
served for complexes I, II and III is fully compatible
with their anticipated structures.
4. Conclusion
The spermidine Pt(II) complexes studied in the
present work revealed themselves as rather e⁄cient
cytotoxic and antiproliferative drugs on the human
cancer cell line HeLa. All the data presented related
to these properties were gathered from two independ-
ent methods: Trypan blue exclusion for determining
cell density and viability, and the MTT colorimetric
assay for assessing cell viability. It was veri¢ed that
compound III displayed the highest cytotoxic and
antitumour e⁄cacy on HeLa cells, with an IC50 value
of 5 WM.
It is well known that the DNA binding pro¢les of
the polyamine polynuclear Pt(II) complexes recently
studied [28^31] are distinctly di¡erent from that of
cisplatin, namely in the high percentage of long-
range (Pt,Pt) interstrand cross-links (which depend
on the polyamine chain length). Moreover, com-
pounds displaying novel mechanisms of action may
eventually circumvent resistance to drugs currently in
clinical use (being active against cisplatin-resistant
tumours).
The results obtained in this work allow us to con-
clude that the conformational preferences of the
Pt(II) complexes, under physiological conditions,
are determinant of their antitumour activity through
induction of DNA structural rearrangements,
namely: (i) the nature (e.g. £exibility) of the poly-
amine ligand(s); (ii) the characteristics of the leaving
groups at the platinum (usually chloride atoms);
(iii) the number and coordination mode of the metal
ion(s); (iv) the distance between the metal centres
within the molecule and their chemical environment
(which is basically constituted by a di- or triamine
and a di- or monochloro moiety). Thus, the design of
new, more e¡ective anticancer drugs should be ruled
by these crucial factors, since slight changes in either
the polyamine conformation or the metal coordina-
tion are su⁄cient to signi¢cantly modify both the
cytotoxic and the antiproliferative activity of this
kind of compounds on tumour cell lines. Moreover,
some relevant criteria for future, third-generation,
Pt(II) drugs should be considered, namely: (i) good
water solubility and stability under physiological
conditions; (ii) absence of undesired parallel reac-
tions and optimized hydrolysis processes within the
cell. Furthermore, tissue speci¢city and low toxicity
towards healthy cells are also goals hopefully to be
achieved in the near future. In order to obtain such
kind of information regarding the complexes present-
ly reported, comparative data are already being gath-
ered with di¡erent human cancer cell lines as well as
with normal ¢broblasts.
Overall, in polynuclear Pt(II) complexes contain-
ing linear amines acting as amplifying linkers, such
as the ones studied in the present work, combination
of the polyamine e¡ects ^ electrostatic, hydrophobic
and hydrogen bond-type interactions ^ with the co-
ordination abilities of the metal centre leads to a
greater e⁄ciency at inducing DNA conformational
changes (e.g. BCZ transitions). The biological activ-
ity of this kind of compounds may then be system-
atically varied through either the ligand characteris-
tics or the geometry of the Pt(II) coordination
sphere. These studies are currently in progress in
our laboratory.
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